Amgen: annual targets tightened

(CercleFinance.com) - On unveiling its quarterly results on Tuesday evening, healthcare group Amgen announced a tightening of its main annual target ranges, compared with its estimates presented three months ago.


For FY 2024, it now expects adjusted EPS (non-GAAP) of between $19.10 and $20.10 (instead of $19 to $20.20) and revenues of between $32.8bn and $33.8bn (instead of $32.5bn to $33.8bn).

With a strong and balanced product portfolio on the market and a rapidly advancing pipeline, we are confident in our ability to generate attractive long-term growth, said CEO Robert A. Bradway.

For Q2 2024, Amgen reported adjusted EPS down 1% to $4.97, with a non-GAAP operating margin down 4.4 points to 48.2% on revenues up 20% to $8.4bn.


Copyright (c) 2024 CercleFinance.com. All rights reserved.